Simultaneous determination of pyrazinamide, rifampicin, ethambutol, isoniazid and Acetyl Isoniazid in human plasma by LC-MS/MS method
ISSN
22313354
Năm xuất bản
2018
Tác giả
Luyen L.T.
Luyen L.T., School of Medicine and Pharmacy, VNU
Hung T.M.
Hung T.M., Center for Bioequivalence Assessment, National Institute of Drug Quality Control, VNU
Huyen L.T.
Huyen L.T., Center for Bioequivalence Assessment, National Institute of Drug Quality Control, VNU
Tuan L.A.
Tuan L.A., School of Medicine and Pharmacy, VNU
Huong D.T.L.
Huong D.T.L., School of Medicine and Pharmacy, VNU
Duc H.V.
Duc H.V., Center for Bioequivalence Assessment, National Institute of Drug Quality Control, VNU
Tung B.T., School of Medicine and Pharmacy, VNU
DOI
10.7324/JAPS.2018.8910
Tóm tắt
Monitoring of anti-tuberculosis drug concentrations in human plasma is very important in the treatment of TB disease. In this study, we described a method that can rapidly and simultaneously measure the plasma concentrations of four anti-tuberculosis drugs (isoniazid, rifampicin, pyrazinamide, and ethambutol) and one major metabolite (acetylisoniazid) using high-performance liquid chromatography/tandem mass spectrometry (HPLC/MS/MS). To adjust for degradation and losses during sample preparation, Diltiazem hydrochloride was used as an internal standard. Samples were prepared by using protein precipitation with methanol. Four drugs and one metabolite were simultaneously separated by using the high-performance liquid chromatography system with Gemini C18 column and a mobile phase consisting of MeOH and Ammonium acetate 5mM, pH 3.5. The method was found to have high selectivity. Precision estimated by the coefficient of variation was <15% for all drugs. The linear range of the calibration curve for PZA 1.0-100 μg/mL
RIF 0.2-20 μg/mL
INH 0.1-10 μg/mL
AcINH 0.1-10 μg/mL
and EMB 20-5000 ng/mL. The lower limit of quantification was 1 μg/mL
0.2 μg/mL
0.1 μg/mL
0.1 μg/mL and 20 ng/mL, respectively. The results of validation for specificity/selectivity, precision, accuracy, linearity, limit of quantification, recovery, and stability show that the method meets the requirements of a bioanalytical method. Our method may serve well for routine therapeutic monitoring of the first-line anti-TB drugs in patient plasma. © 2018 Le Thi Luyen et al.
